Jazz PharmaceuticalsJAZZ
JAZZ
About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees: 2,800
0
Funds holding %
of 7,363 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
131% more call options, than puts
Call options by funds: $17M | Put options by funds: $7.36M
65% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 54
10% more capital invested
Capital invested by funds: $6.59B [Q3] → $7.26B (+$677M) [Q4]
6% more funds holding
Funds holding: 470 [Q3] → 499 (+29) [Q4]
1.81% more ownership
Funds ownership: 95.84% [Q3] → 97.64% (+1.81%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 9 [Q3] → 9 (+0) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 166 | Existing positions reduced: 170
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$150
10%
upside
Avg. target
$191
40%
upside
High target
$230
68%
upside
11 analyst ratings
10 positive
91%
1 neutral
9%
0 negative
0%
HC Wainwright & Co. Oren Livnat 57% 1-year accuracy 27 / 47 met price target | 59%upside $217 | Buy Maintained | 10 Mar 2025 |
Morgan Stanley Jeffrey Hung 57% 1-year accuracy 16 / 28 met price target | 34%upside $183 | Overweight Assumed | 7 Mar 2025 |
UBS Ashwani Verma 26% 1-year accuracy 5 / 19 met price target | 31%upside $179 | Buy Upgraded | 7 Mar 2025 |
Truist Securities Gregory Fraser 50% 1-year accuracy 1 / 2 met price target | 68%upside $230 | Buy Maintained | 6 Mar 2025 |
Needham Ami Fadia 31% 1-year accuracy 53 / 172 met price target | 53%upside $210 | Buy Reiterated | 5 Mar 2025 |
Financial journalist opinion
Based on 30 articles about JAZZ published over the past 30 days
Neutral
Business Wire
1 day ago
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix that they own. KSF is seeking to determine whether this consideration and the process that led to.
Positive
Zacks Investment Research
1 day ago
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.
Neutral
Zacks Investment Research
4 days ago
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Positive
Zacks Investment Research
5 days ago
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.
Positive
Zacks Investment Research
5 days ago
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain.
Negative
Zacks Investment Research
6 days ago
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
Positive
Benzinga
6 days ago
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
On Tuesday, Jazz Pharmaceuticals plc JAZZ agreed to acquire Chimerix Inc CMRX for $8.55 per share in cash, representing a total consideration of approximately $935 million.
Positive
Reuters
6 days ago
Jazz Pharmaceuticals to buy Chimerix for $935 million
Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday.
Neutral
PRNewsWire
6 days ago
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- - Transaction to add near-term commercial opportunity to Jazz's pipeline- -Transaction represents total cash consideration of approximately $935 m illion, or $8.55 per share- DUBLIN and DURHAM, N.C. , March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million.
Neutral
GlobeNewsWire
6 days ago
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz's pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) and Chimerix (Nasdaq: CMRX) (“Chimerix”), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million.
Charts implemented using Lightweight Charts™